Prevention of Decompression Sickness by Novel Artificial Oxygen Carriers
| Autor: | François Guerrero, Marko Ljubkovic, Katja B. Ferenz, Dirk Mayer, Lisa Hetzel, Christian Mayer, Alfons Kreczy, Jürgen Linders, Michael Kirsch, Christelle Goanvec |
|---|---|
| Rok vydání: | 2020 |
| Předmět: |
Male
medicine.medical_specialty Decompression ALBUMIN-DERIVED PERFLUOROCARBON-BASED ARTIFICIAL OXYGEN CARRIERS NANOCAPSULES NONRECOMPRESSIVE THERAPY RODENTIN VIVOMODEL Chemie Medizin Physical Therapy Sports Therapy and Rehabilitation Spleen Gastroenterology Nanocapsules Decompression sickness 03 medical and health sciences 0302 clinical medicine In vivo Internal medicine medicine Animals Orthopedics and Sports Medicine Rats Wistar Cell damage Serum Albumin Fluorocarbons business.industry Albumin 030229 sport sciences Human serum albumin medicine.disease Decompression Sickness Oxygen Disease Models Animal medicine.anatomical_structure Liver business medicine.drug |
| Zdroj: | Medicine and science in sports and exercise. 52(10) |
| ISSN: | 1530-0315 |
| Popis: | For three decades, studies have demonstrated the therapeutic efficacy of perfluorocarbon (PFC) in reducing the onset of decompression trauma. However, none of these emulsion-based preparations are accepted for therapeutic use in the western world, mainly because of severe side effects and a long organ retention time. A new development to guarantee a stable dispersion without these disadvantages is the encapsulation of PFC in nanocapsules with an albumin shell. Purpose Newly designed albumin-derived perfluorocarbon-based artificial oxygen carriers (A-AOC) are used in a rodent in vivo model as a preventive therapy for decompression sickness (DCS). Methods Thirty-seven rats were treated with A-AOC (n = 12), albumin nanocapsules filled with neutral oil (A-O-N, n = 12), or 5% human serum albumin solution (A-0-0, n = 13) before a simulated dive. Eleven rats, injected with A-AOC, stayed at normal pressure (A-AOC surface). Clinical, laboratory, and histological evaluations were performed. Results The occurrence of DCS depended on the treatment group. A-AOC significantly reduced DCS appearance and mortality. Furthermore, a significant improvement of survival time was found (A-AOC compared with A-0-0). Histological assessment of A-AOC-dive compared with A-0-0-dive animals revealed significantly higher accumulation of macrophages, but less blood congestion in the spleen and significantly less hepatic circulatory disturbance, vacuolization, and cell damage. Compared with nondiving controls, lactate and myoglobin showed a significant increase in the A-0-0- but not in the A-AOC-dive group. Conclusion Intravenous application of A-AOC was well tolerated and effective in reducing the occurrence of DCS, and animals showed significantly higher survival rates and less symptoms compared with the albumin group (A-0-0). Analysis of histological results and fast reacting plasma parameters confirmed the preventive properties of A-AOC. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|